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Abstract
In the last two and half decades, we have conducted research on brain functional 
imaging in nonhuman primates using animal positron emission tomography (PET) 
scanners with high spatial resolution. We recently designed and synthesized the 
novel PET probe [18F]BCPP-EF to quantitatively image mitochondria complex-I 
(MC-I) activity in the living brain. Brain MC-I activity, measured using [18F]
BCPP-EF, was significantly lower in aged monkeys than that in young animals, 
while no significant reduction was observed in SV2A activity, a synaptic-specific 
parameter that was measured using [11C]UCB-J. Some aged monkeys exhibited 
increased amyloid-β deposition in the brain, measured using [11C]PiB, which 
induced neuroinflammation. A positive correlation was noted with neuroinflamma-
tion, measured using [11C]DPA-713 and a negative correlation with MC-I activity. 
Furthermore, a monkey model of Parkinson’s disease prepared by the chronic 
administration of MPTP revealed suppressed MC-I activity not only in the nigros-
triatal dopamine pathway, measured using [11C]PE2I and [11C]6MemTyr, but also in 
cortical serotonergic neurons, measured using [11C]DASB. This review introduces 
the translational application of a novel PET probe for noninvasive MC-I imaging 
from preclinical to clinical PET measurements.
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1. Introduction
The brain has the most complex system among all human organs and plays a 
central role in physiological, neurological, and metabolic regulation throughout the 
body. The brain is very metabolically active in proportion to its volume, consuming 
20% of total oxygen and 25% of total glucose, and each cell relies on mitochondria 
to produce energy as adenosine triphosphate (ATP). The brain consists of neuronal 
and glial cells, each of which uses the different metabolic pathways to produce ATP; 
astrocytes are highly glycolytic, while neurons depend on oxidative phosphoryla-
tion (OXPHOS) in the mitochondria [1]. The electron transport chain (ETC) for 
OXPHOS in mitochondria consists of five types of complexes from I to V, with 
complex-I (MC-I; NADH–ubiquinone oxidoreductase, EC 1.6.5.3) forming the first 
and rate-limiting steps of overall respiratory and OXPHOS.
Neuronal death is regarded the dominant cause of brain aging. The 
“Mitochondrial Free Radical Theory of Aging” considers mitochondria to be the 
main drivers of aging due to the generation of reactive oxygen (ROS) and nitrogen 
(RNS) species through the ETC, and the cumulated impairment of mitochondria 
by oxidative stress in mitochondrial lipids, proteins, and DNA leads to neuronal 
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death in the brain [2]. Neuronal damage related to impaired mitochondrial func-
tion is a hallmark for several neurodegenerative diseases, including Alzheimer’s 
(AD), Parkinson’s (PD), Huntington’s diseases (HD), as well as amyotrophic lateral 
sclerosis (ALS) and multiple sclerosis (MS).
The etiology of AD, the most prominent age-related neurodegenerative disease, 
is multifactorial and associated with various environmental and genetic factors that 
play a role in its pathogenesis. The deposition of amyloid-β (Aβ) in the brain has 
been suggested to enhance neurodegenerative damage. Structural disruption and 
loss of neuronal cells induced by Aβ, leading to neuronal network dysfunction and 
synaptic loss in the hippocampus and cerebral cortex, is associated with cognitive 
impairment in AD patient [3]. Although the molecular mechanisms underlying 
synaptic dysfunction induced by Aβ have not been fully elucidated, mitochondrial 
dysfunction caused by Aβ is associated with synaptic functional alterations in the 
living brain [3].
PD is the second most prominent neurodegenerative disease and is character-
ized by the progressive degradation of the nigrostriatal pathway with the selective 
loss of dopamine (DA) neurons, resulting in movement abnormalities such as 
resting tremor, rigidity, akinesia, and impaired postural reflexes. A hallmark of 
idiopathic PD is the deposition of Lewy bodies containing insoluble and aggregated 
α-synuclein in the cytoplasmic fraction of nigrostriatal neurons in the DA pathway 
[4]. The loss of MC-I catalytic activity in the ETC has been reported in tissues 
obtained from sporadic PD patients [5] with increased oxidative stress [6].
Regarding the noninvasive assessment of mitochondrial function in the living 
brain, we recently developed a novel probe, [18F]2-tert-nutyl-4-chloro-5-{6-[2-(2-
fluoroethyl)-ethoxyl-pyridin-3-3-ylmetoxy]-2H-pyrisazin-3-one ([18F]BCPP-EF), 
for positron emission tomography (PET) [7]. The effects of physiological aging, 
aging-related Aβ deposition, and chronic MPTP treatments on cortical MC-I 
function were assessed in conscious monkeys using [18F]BCPP-EF, with the aim of 
translating clinical PET research to AD and PD patients.
2. Effects of aging on MC-I and SV2A function in the living brain
Mitochondria from aged brains consume less oxygen and, thus, produce lower 
amounts of ATP [8]. Different types of neurons show differences in topologies 
with various numbers of synaptic connections. Since synaptic and non-synaptic 
mitochondria have different protein compositions and respiratory and ROS produc-
tion rates, synaptic mitochondria are more vulnerable to oxidative damage during 
the aging process than non-synaptic mitochondria [9]. In quantitative assessments 
of the effects of physiological aging on mitochondria and synaptic function in the 
living brain, the activities of MC-I and synaptic vesicle glycoprotein 2A (SV2A), 
an ideal biomarker for synaptic density, were comparatively evaluated in the living 
brains of young and aged rhesus monkeys.
2.1 Methods
Six young male (3–5 years old) and eight aged male (20–24 years old) rhesus 
monkeys (Macaca mulatta) were examined in the PET study using [18F]BCPP-EF for 
MC-I and (R)-1-((3-[11C]methyl-[11C])pyridine-4-yl)methyl)-4-(3,4,5-trifluoro-
phenyl)pyrrolidin-2-one ([11C]UCB-J) for SV2A [10]. MRI was performed on each 
monkey using a 3.0 T MR imager (Singna Excite HDxt 3.0 T, GE Healthcare) using a 
3D spoiled gradient echo (SPGR) sequence under pentobarbital anesthesia. To avoid 
anesthetic effects on brain function as well as PET probe kinetics, PET scans were 
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conducted under conscious condition using high-resolution animal PET scanners 
(SHR-7700 and 38,000, Hamamatsu Photonics) as reported previously [11–14].
[18F]BCPP-EF was prepared by the nucleophilic [18F] fluorination of the cor-
responding precursor, as reported previously [9]. Radiochemical purity was more 
than 99%, and specific radioactivity was 47.8 ± 12.7 GBq/μmol. [11C]UCB-J was 
labeled via the Suzuki cross-coupling of [11C]methyl iodide with a boronate precur-
sor, as reported previously [10]. Radiochemical purity was more than 98%, and 
specific radioactivity was 62.3 ± 25.1 GBq/μmol.
After overnight fast, a venous cannula for the PET ligand injection and an 
arterial cannula for blood sampling were inserted into both inferior limbs. The 
animal’s head was rigidly fixed to a monkey chair using an acrylic head-restraining 
device surgically attached on the skull. The monkey sitting in the chair was placed 
at a position in the PET gantry with stereotactic coordinates aligned parallel to 
the orbito-metal (OM) plane. After a transmission scan for 30 min using a [68Ge]-
[68Ga] rotation rod source, a dynamic emission scan with [18F]BCPP-EF or [11C]
UCB-J was conducted for 90 min after the PET probe injection as a bolus.
To assess the specificity of [18F]BCPP-EF binding to MC-I, which was previ-
ously examined in rats [15], rotenone, an MC-I inhibitor, at a dose of 0.1 mg/kg 
was infused into young monkeys through a vein cannula for 1 h, followed by [18F]
BCPP-EF injection.
PET data were reconstructed by the dynamic row action maximum likelihood 
algorithm (DRAMA) method using a 2.0-mm Gaussian post filter [16], with attenu-
ation correction using transmission scan data. Individual PET and MRI images were 
co-registered. Volumes of interest (VOIs) in brain regions were drawn manually 
on MRI, and the time activity curve (TAC) of each PET probe was taken for kinetic 
analyses. These imaging annalistic processes were performed using PMOD software 
(PMOD Technologies Ltd.).
In a quantitative analyses of [18F]BCPP-EF and [11C]UCB-J, arterial blood 
samples were frequently obtain after the PET probe injection, centrifuged to sepa-
rate plasma, and ethanol was added to some plasma samples, followed by centrifu-
gation. The supernatants obtained were developed with thin layer chromatography 
with a mobile phase of ethyl acetate for [18F]BCPP-EF and chloroform/metha-
nol = 9:1 for [11C]UCB-J, respectively. The ratio of the unmetabolized fraction was 
assessed using a phosphoimaging plate analyzed by a bioimaging analyzer (FLA-
7000, GE Healthcare).The arterial input function of unmetabolized [18F]BCPP-EF 
or [11C]UCB-J was calculated using data obtained by a correction of the radioactiv-
ity ratio in the unmetabolized fraction to total fraction. A kinetic analysis of [18F]
BCPP-EF or [11C]UCB-J was performed to calculate distribution volume (VT) using 
a Logan graphical analysis [17] with PMOD software (PMOD Technologies Ltd.).
2.2 Results
Brain TACs of [18F]BCPP-EF in young animals peaked at approximately 15 min 
after the injection, except in the occipital cortex, which peaked at 40 min, and 
TACs then were gradually eliminated with time under conscious condition. The 
pre-administration of rotenone resulted in a faster elimination rate of [18F]BCPP-EF 
from the brain than that in normal. In aged animals, the peak time of TACs shifted 
to slightly later after the injection and showed significant lower [18F]BCPP-EF 
uptake levels than those in young animals.
The washout of [18F]BCPP-EF-related radioactivity and its metabolites rate 
in plasma were very rapid, with only 10% of the non-metabolized parent probe 
remaining 60 min after the injection. These kinetic patterns of [18F]BCPP-EF were 
almost identical among control young, rotenone-treated young, and aged animals. 
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A metabolic analysis confirmed that its metabolites were very polar, indicating no 
uptake of metabolites into the brain through the blood–brain barrier. These results 
confirmed that this PET probe has ideal properties for the quantitative analysis of 
MC-I activity using a metabolite-corrected arterial input function.
As shown in the upper panel of Figure 1, VT -PET images of young brains indi-
cated that the binding of [18F]BCPP-EF was highest in the occipital cortex, higher in 
the striatum, intermediate in the frontal and temporal cortices and cerebellum, and 
lowest in the hippocampus. The pre-administration of rotenone at a dose of 0.1 mg/
kg/h significantly reduced the uptake of [18F]BCPP-EF into the young monkey 
brain, specifically in the frontal and temporal cortices and striatum. When aging 
effects on VT -PET images were assessed, the binding of [
18F]BCPP-EF throughout 
the brain was significantly lowered in aged animals than in young animals, as 
shown in the lower panel of Figure 1.
The TAC of [11C]UCB-J in young animals exhibited slower kinetics than [18F]
BCPP-EF throughout the brain regions, peaking approximately 30 min after the 
injection, and TACs gradually decreased with time under conscious conditions. TACs 
in aged animals peaked 30 min after the injection and showed slightly lower [11C]
UCB-J uptake levels than those in young animals. The washout of [11C]UCB-J-related 
radioactivity and metabolic rates in plasma were slower than those of [18F]BCPP-EF, 
with 25% of the non-metabolized parent probe remaining 60 min after the injection. 
These kinetic patterns of [18F]BCPP-EF were not significantly different between 
young and aged animals. A metabolic analysis confirmed that its metabolites were 
very polar, suggesting no uptake of the metabolites into the brain through the blood–
brain barrier. These results confirmed that this PET probe is useful for the quantita-
tive analysis of SV2A activity using a metabolite-corrected arterial input function.
As shown in the upper panel of Figure 2, VT -PET images of the young brain 
revealed the highest binding of [11C]UCB-J in the frontal, temporal, and occipital 
Figure 1. 
Effects of aging on PET images of MC-I in living brains of conscious monkeys. PET scans were conducted for 
91 min using [18F]BCPP-EF for MC-I, and VT images of [
18F]BCPP-EF were created using a Logan graphical 
plot analysis with metabolite-corrected plasma input.
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cortices, higher in the striatum, intermediate in the hippocampus, and the lowest 
in the cerebellum. Thus, the distribution pattern of [11C]UCB-J resembled to that of 
[18F]BCPP-EF throughout the brain of young animal.
However, in contrast to [18F]BCPP-EF, when the VT of [
11C]UCB-J was compared 
between young and aged monkeys, no significant age-related changes in cerebral 
SV2A activity were detected except the olfactory bulb, as shown in the lower panel 
of Figure 2.
2.3 Discussion
The present results showed age-related reduction in mitochondria function 
assessed by MC-I activity using [18F]BCPP-EF, as reported previously [11], while 
no significant alterations in synaptic density were observed based on SV2A activity 
using [11C]UCB-J.
We evaluated [18F]BCPP-EF by in vitro (living brain slices), ex vivo (dissected 
tissues), and in vivo (living rat brains) assessments in comparison with the conven-
tional MC-I PET probe, [18F]BMS-747158-02 ([18F]BMS), which was developed as a 
myocardial perfusion PET imaging probe [18], and the results obtained suggested 
that [18F]BCPP-EF is a more suitable PET probe than [18F]BMS for MCI assessments 
in the living brain [7, 15]. [18F]BCPP-EF was characterized by (1) high specific bind-
ing with moderate affinity, (2) a proper logD7.4 value, (3) long metabolic stability 
with fast clearance in plasma, (4) sufficient brain uptake with a proper elimination 
rate from the brain, and (5) low dependency to cerebral blood flow changes [19]. 
As a PET probe, these properties of [18F]BCPP-EF may contribute for a noninvasive 
and quantitative analysis of MC-I in the living brain [11], thereby allowing for the 
high detectability of age-related reductions in MC-I activity in the living monkey 
brain. Although several postmortem in vitro studies previously reported that (1) 
Figure 2. 
Effects of aging on PET images of SV2A in living brains of conscious monkeys. PET scans were conducted for 
91 min using [11C]UCB-J for SV2A, and VT images of [
11C]UCB-J were created using a Logan graphical plot 
analysis with metabolite-corrected plasma input.
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age-related brain MC-I impairments were associated with a decline in mitochondria 
respiration [20, 21] and (2) the activities of MC-I and -IV, but not MC-II, III, or V, 
decreased with aging in the brains of rodents [22] and humans [20, 21], this study 
was the first to successfully confirm age-related reductions in MC-I activity in the 
living brain of nonhuman primates [11].
As described above, [18F]BCPP-EF detected age-related reduction in MC-I activ-
ity; however, this PET probe was unable to discriminate the subdomain (synapse, 
dendrites, or soma) of MC-I that was exclusively damaged due to the limitation 
of the spatial resolution of PET. In attempts to answer this question, [11C]UCB-J, 
a novel PET probe for SV2A [10], was applied to the same subject groups on the 
assumption that if this MC-I reduction mainly reflected the presynaptic domain, 
the binding of [11C]UCB-J to SV2A will also show a similar age-related reduction 
pattern in the brain. However, contrary to this assumption, no significant changes 
in [11C]UCB-J binding to SV2A were observed, except the olfactory bulb, from those 
in the same young and aged animals applied in the assessment using [18F]BCPP-EF.
Several postmortem in vitro studies have suggested age-related reductions in 
spine density; however, these findings remain controversial. One study using rat 
brains revealed that the synaptic vesicle density in axospinous synapse, a major 
population of synapses, rapidly increased until 3 weeks old and then decreased to 
the adult level, followed by no changes in senescence [23]. However, another study 
on mouse brain showed that age-related deficits in sensory perception were not 
associated with synaptic loss in the somatosensory cortex but were related to altera-
tions in the size and stability of spine buttons [24], which might not be detected as 
the changes in SV2A activity.
The discrepancy in age-related effects between [11C]UCB-J and [18F]BCPP-EF sug-
gest that MC-I dysfunction detected by [18F]BCPP-EF mainly reflect neuronal damage 
in dendrite and soma domains and are not specific to presynaptic domain. Although 
difficulties are associated with assessing mitochondrial distribution in neuronal cells, 
it was demonstrated in the cultured neuron that more than 90% of mitochondria 
were confirmed to be in the dendrite shaft overlapping in soma and large-diameter 
proximal dendrites [25]. This localized distribution pattern of the mitochondria sug-
gests that even if mitochondria in the presynaptic domain are specifically impaired, 
difficulties may be associated with detecting changes in the minor subdomain using 
[18F]BCPP-EF. The present results also suggested that in the early stage of the aging 
process, at least, in nonhuman primates, neuronal damage in the synaptic domain, if 
any, may be too subtle to be detected as decreased [11C]UCB-J binding to SV2A.
3. Effects of amyloid-β deposition on MC-I function in the living brain
Patients of AD, the most prominent age-related neurodegenerative disease, are 
characterized by the deposition of fibrillary Aβ into senile plaques and hyperphos-
phorylated tau (P-tau) into neurofibrillary tangle (NFT) in the brain. Monomer Aβ 
has been implicated in normal developmental synaptic plasticity, for example, in 
the olfactory bulb under physiological conditions [26]. However, the aggregation 
of Aβ switches its physiological role into a pathologically toxic function; thus dense 
plaques damage the surrounding brain tissues [27], causing synaptic elimination 
and impaired synaptic function [28]. Although the molecular mechanisms underly-
ing neuronal damage induced by Aβ have not been fully elucidated, mitochondrial 
dysfunction may be associated with Aβ-induced synaptic dysfunction [3] and also 
with neuroinflammation [29], resulting in cognitive impairment in AD patients. In 
order to clarify the relationship between Aβ deposition, neuroinflammation, and 
mitochondrial function, [11C]PiB for Aβ [30], [11C]DPA-713 for translocator protein 
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(TSPO) [31], and [18F]BCPP-EF for MC-I were comparatively evaluated in the 
living brains of aged rhesus monkeys. Furthermore, as a gold standard parameter of 
cerebral metabolism, [18F]fluoro-2-deoxy-D-glucose ([18F]FDG) was also applied to 
compare the diagnostic and prognostic usefulness with [18F]BCPP-EF.
3.1 Methods
Twenty aged male (20–24 years old) rhesus monkeys (Macaca mulatta) were 
investigated in the PET study using [11C]PiB for Aβ, [11C]DPA-713 for TSPO, and 
[18F]BCPP-EF for MC-I under conscious conditions using a high-resolution PET 
scanner as described in 2.1.
[11C]PiB was synthesized by the N-methylation of nor-compound N-desmethyl-
PiB with [11C]methyl triflate [30]. Radiochemical purity was more than 99%, 
and specific radioactivity was 36.7 ± 10.1 GBq/μmol. [11C]DPA-713 was syn-
thesized by the N-methylation of nor-compound N-desmethyl-DPA with [11C]
methyl triflate [31]. Radiochemical purity was more than 99%, and specific 
radioactivity was 99.3 ± 32.2 GBq/μmol. [18F]BCPP-EF was radiolabeled as 
shown in 2.1. Radiochemical purity was more than 99%, and specific radioac-
tivity was 139.6 ± 37.0 GBq/μmol. [18F]FDG was produced by the nucleophilic 
[18F]fluorination of mannose triflate following the basic hydrolysis of 2-[18F]
fluoro-1.3.4.6-tetra-O-acetyl-D-glucose.
In the analysis of [11C]PiB, standard uptake value (SUV) images from 60 to 
90 min were created, VOIs were set on each SUV images, and the SUV ratios 
(SUVR) of each region (SUVreg) against SUV in the cerebellum (SUVcereb) were 
calculated [32]. In the analysis of [11C]DPA-713, SUV images from 40 to 60 min 
were created, and VOIs were set on each SUV image. Since any cerebral regions were 
not applicable as the reference region with negligible TSPO levels [33], the SUV, 
not SUVR, was assessed. A quantitative analysis of [18F]BCPP-EF was performed as 
described in 2.1. During PET scanning with [18F]FDG, continuous arterial sam-
pling was conducted, and PET images from 40 to 60 min after the injection were 
obtained to calculate the regional cerebral metabolic rate of glucose (rCMRglc) 
using an autoradiographic method. The rCMRglc ratios of each region (rCMRglc-
region) against rCMRglc in the cerebellum (rCMRglc-cere) were calculated [34].
3.2 Results
Since the cortical VT values of [
18F]BCPP-EF in aged monkeys were previously 
shown to have a higher CV value of ca. 25% than those in young ones of ca. 7% 
[11], the reasons for the lager variation of MC-I activity were elucidated using PET 
imaging with [11C]PiB for Aβ deposition and [11C]DPA-713 for TSPO in 20 aged 
monkeys. Figure 3 shows the PET/MRI images of aged monkeys with the lowest (A) 
and highest (E) [11C]PiB binding, with high SUV not only being detected in cortical 
but also subcortical regions. PET results obtained with [11C]PiB were supported 
by an immunohistochemical assessment conducted after PET assessments [12]. 
The images of [11C]DPA-713 (B and F) corresponding to each monkey (A and E) 
revealed that monkeys with the lowest (A) and highest (E) [11C]PiB binding showed 
the lower (B) and higher (F) [11C]DPA-713 binding. In contrast, the images of [18F]
BCPP-EF corresponding to each monkey with the lowest (A) [11C]PiB binding 
exhibited higher [18F]BCPP-EF uptake (C), while those with the highest [11C]PiB 
binding (E) showed the lower [18F]BCPP-EF uptake (G).
As shown in Figure 4A, when the SUV values of [11C]DPA-713 were plot-
ted against the SUVR of [11C]PiB in the cortical VOIs of all animals, the results 
obtained revealed a significant positive correlation between each parameter, 
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indicating that Aβ deposition-induced neuroinflammation in the living brains of 
aged monkeys. In contrast, the plotting of VT of [
18F]BCPP-EF against SUVR of 
[11C]PiB showed a reverse correlation in the cortical VOIs of all animals, suggest-
ing that Aβ deposition-induced MC-I impairments in the brains of aged monkeys 
(Figure 4B).
Based on Figures 3H and 4C, it is important to note that a correlation was not 
observed between glucose metabolism assessed as the SUVR of [18F]FDG and Aβ 
deposition measured as the SUVR of [11C]PiB, and this may have been due to [18F]
FDG uptake into the neuroinflammation-related activated microglial cells.
Figure 3. 
Effects of Aβ deposition on PET images of [11C]PiB (A and E), [11C]DPA-713 (B and F), [18F]BCPP-EF (C 
and G), and [18F]FDG (D and H) in living brains of conscious monkeys. PET scans were conducted in monkey 
with the lowest (A–D) and highest (E-H) Aβ deposition among 20 aged monkeys.
Figure 4. 
Correlations between the SUV of [11C]DPA-713 (A), VT of [
18F]BCPP-EF (B), and rCMRglc ratio of [18F]
FDG (C) against the SUVR of [11C]PiB in cortical and hippocampal regions of living brains of aged monkeys.
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3.3 Discussion
The present results demonstrated the potential of MC-I impairment assessed 
using [18F]BCPP-EF as a useful biomarker for Aβ deposition-related neurodegen-
eration, measured using [11C]PiB, and neuroinflammation, measured using [11C]
DPA-713. In contrast, the assessment of rCMRglc using conventional [18F]FDG was 
not as sensitive for detecting the neurodegenerative damage associated with inflam-
mation in the early stage of disease onset because of [18F]FDG uptake into not only 
normal neuronal cells but also into inflammatory cells, such as activated microglia 
in the brain [15, 19, 29]. Since activated microglia dominantly facilitate glycolysis, 
not ORPHOS system through mitochondria, to produce ATP, more glucose is 
required in microglia than in normal neuron, resulting in higher [18F]FDG uptake 
than in normal cells. Thus, MC-I assessed using [18F]BCPP-EF has a potential as a 
biomarker to assess neurodegeneration more accurately without being affected by 
inflammation in the living brain.
The present PET images obtained using [11C]PiB did not reveal as prominent 
Aβ deposition in aged monkey brains as that in the brains of PD patients. Previous 
studies suggested that no species other than humans exhibited marked neuron 
loss or cognitive impairment observed as clinical grade AD in humans, and aged 
monkeys did not exhibit as high Aβ deposition as seen in AD patients [35] or [11C]
PiB binding [36] as that in AD patients. Therefore, we assumed that the aged 
monkey model exhibited a similar mild cognitive impairment (MCI)-like, not 
AD-like, state to that in humans. In the AD state after a lag period of MCI, Aβ 
deposition level reached a plateau; therefore no correlation was observed between 
[11C]PiB uptake and cognitive levels or metabolic dysfunction assessed using 
[18F]FDG [37]. In contrast, [11C]PiB may function as a quantitative and sensitive 
biomarker for Aβ-related neuronal damage in aged monkey brains resembling the 
MCI-like state in humans [38]. Furthermore, a recent study reported the primary 
role of non-deposited, non-fibrillar assembles of Aβ peptides, and, thus, they may 
become precursors for fibrillogenesis, which lead to oxidative neurotoxicity by ROS 
in the brains of very early stage of AD patients [39]. ROS-related mitochondrial 
OXPHOS failure in the brain has been implicated in neurodegenerative disorders 
[40]. Mitochondria are the main intercellular source of ROS and also the main 
target of oxidative damage, leading to the significant disruption of brain function. 
A recent study demonstrated the direct effects of Aβ on mitochondria; thus, in 
addition to extracellular deposition, Aβ was detected in cytoplasmic mitochondria 
compartments [41], leading to dysfunction with the suppressed availability of 
nucleus-encoded proteins, a decreased rate of NABH reduction, and enhanced ROS 
generation [42]. Since we previously confirmed a positive correlation between the 
VT of [
18F]BCPP-EF and rCMRO2, a gold standard for brain activation [19], the Aβ 
deposition-related MC-I functional impairment observed in the present study may 
reflect diminished activity and/or the loss of neurons with neuroinflammation. The 
present study revealed a correlation between [11C]PiB binding and [18F]BCPP-EF 
uptake, demonstrating the usefulness of an assessment of MC-I for the diagnostic 
staging of MCI and early stage AD.
In the present study, TSPO activity evaluated using [11C]DPA-713, an index of 
neuroinflammation, was stronger in the aged monkey brain with higher [11C]PiB 
binding to Aβ. Furthermore, [11C]DPA-713 binding to TSPO and rCMRglc measured 
using [18F]FDG revealed a correlation (data not shown) [12]. These results suggest 
Aβ deposition-induced neuroinflammation with the activation of microglial cells.
Therefore, the detectability of MC-I impairment using [18F]BCPP-EF for neuro-
nal damage in AD appears to be superior to the assessment of glucose metabolism 
measured using conventional [18F]FDG.
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4. Effects of MPTP-induced parkinsonism on MC-I in the living brain
Patients with PD show the progressive degradation of the nigrostriatal path-
way with the selective loss of DA neurons in the substantia nigra pars compacta 
(SNc), resulting in movement disorders, which are induced after the loss of ca. 
50% of neurons in the SNc and a reduction in DA to ca. 20% of normal levels 
in the striatum [43]. A pathological hallmark of PD is Lewy bodies and Lewy 
neurites, containing intracytoplasmic insoluble and aggregated protein of 
α-synuclein [4]. The spread of these pathologies closely correlates with disease 
progression. Furthermore, an intracerebral injection of insoluble α-synuclein 
converted normal α-synuclein into an abnormal form, which then propagated 
throughout the brains of monkeys [44] and common marmosets [45]. The 
soluble, β sheet-rich oligomers of α-synuclein induced mitochondrial dysfunc-
tion by inhibiting MC-I, enhancing ROS production, and activating the mito-
chondrial permeability transition pore (PTP), leading to mitochondrial swelling 
and neuronal death [46].
Since exposure to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) 
induces a syndrome mimicking PD symptoms accompanied by selective DA dam-
age in the nigrostriatal pathway [47], we developed a PD model of monkeys by 
systemic and repeated MPTP administration [48, 49] and evaluated serotonin 
(5-HT) transporter (SERT) availability using [11C]-3-amino-4-(2-dimethylamino-
methylphenylsulfanyl)-benzonitrile ([11C]DASB) [50] 5-HT 1A receptor (5-HT1AR) 
binding using 4-(2′-methoxyphenyl)-1-[2′-(N-2″-pyridinyl)-p-[18F]fluoro-benza-
mido]ethylpiperazine ([18F]MPPF) [51] in parallel with DA parameters for presyn-
aptic DA synthesis (DAS) using 6-[11C]methyl-m-tyrosine ([11C]6MemTyr) [52, 
53], DA transporter (DAT) using [11C]N-(3-iodoprop-2E-enyl)-2β-carbomethoxy-
3β-(4-methyl-phenyl) nortropane ([11C]PE2I) [54], postsynaptic DA D2R using 
[11C]Raclopride, and MC-I activity using [18F]BCPP-EF in the living brains of 
MPTP-treated monkeys [13].
4.1 Methods
Young adult male rhesus monkeys (Macaca mulatta) were used to prepare the 
PD model, as reported previously [48, 49]. MPTP at doses ranging between 0.2 and 
0.4 mg/kg in phosphate-buffered saline was injected intravenously over a 4-month 
period until stable Parkinsonian syndrome developed. MPTP-treated monkeys were 
subjected to PET scans using specific PET probes for DA, 5-HT neuronal systems, 
and MC-I under conscious condition using a high-resolution PET scanner, as 
described in 2.1. In order to avoid the potential for spontaneous recovery as well as 
direct inhibition of [18F]BCPP-EF binding to MC-I by MPTP, all PET measurements 
were started at least after 2 months after the last treatment with MPTP.
[11C]PE2I was radiolabeled by the O-[11C]methylation of its nor-compound with 
[11C]methyl triflate. Radiochemical purity was more than 98% and specific radio-
activity of 117.1 ± 42.9 GBq/μmol. [11C]6MemTyr was developed in our laboratory 
using rapid Pd(0)-mediated cross-coupling between [11C]methyl iodide and its 
boronate precursor [52, 53], showing radiochemical purity of more than 99% and 
specific radioactivity of 71.6 ± 37.4 GBq/μmol. [11C]Raclopride was radiolabeled by 
N-[11C]methylation of its nor-compound with [11C]methyl triflate. Radiochemical 
purity was more than 98% and specific radioactivity of 65.4 ± 15.8 GBq/μmol. 
[18F]BCPP-EF was radiolabeled as shown in 2.1. Radiochemical purity was more 
than 99%, and specific radioactivity was 58.9 ± 7.9 GBq/μmol. [11C]DASB was 
prepared by the N-[11C]methylation of its nor-compound with [11C]methyl triflate 
[50] with radiochemical purity of more than 99% and specific radioactivity of 
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47.6 ± 11.1 GBq/μmol. [18F]MPPF was synthesized by the nucleophilic [18F]fluorina-
tion of its nitro precursor [51] with radiochemical purity of more than 99% and 
specific radioactivity of 90.4 ± 25.6 GBq/μmol.
Quantitative analyses of [11C]PE2I, [11C]Raclopride, [11C]DASB, and [18F]
MPPF were performed with a simplified reference tissue model to calculate 
non-displaceable binding potential (BPND) [55] using PMOD software (PMOD 
Technologies Ltd., Zurich, Switzerland). As an indirect input function, TAC in the 
cerebellum was applied. A quantitative analysis of [18F]BCPP-EF was performed as 
described in 2.1. A quantitative analysis of [11C]6MemTyr to calculate the Ki value 
was performed using a multiple-time graphical analysis [56] using PMOD software 
(PMOD Technologies Ltd., Zurich, Switzerland) applying the TAC in the occipital 
cortex as an input function.
4.2 Results
The effects of chronic MPTP treatments on the DA neuronal system in the 
brain were revealed in Figure 5. PET measurements using [11C]PE2I for DAT (A), 
[11C]6MemTyr for DAS (B), and [11C]Raclopride for D2R (C) clearly imaged the 
striatum of the normal monkey brain. After the repeated treatment with MPTP, 
presynaptic DAT availability assessed using [11C]PE2I was significantly lower in the 
caudate (4.0% of normal), putamen (4.9% of normal), and SNc (18.6% of normal) 
(E) of the MPTP-treated monkey brain than in the normal monkey (A). Another 
presynaptic parameter of DAS assessed using [11C]6MemTyr was also markedly 
lower in the caudate (13.6% of normal), putamen (12.3% of normal), and SNc (41.1% 
of normal) (F) of MPTP monkey brain than in normal animal monkey brain (B). In 
contrast, no significant changes in [11C]Raclopride binding to postsynaptic D2R were 
observed in the striatum or SNc between normal (C) and MPTP-treated animals (G).
The effects of the MPTP treatments on PET images of MC-I in the brain are shown 
in Figure 5D and H. The cerebral uptake of [18F]BCPP-EF in normal monkeys showed 
homogeneous and symmetric patterns in the both hemispheres with clear separation 
of the cortical and basal ganglion regions (D). After the repeated treatment with 
MPTP, the VT of [
18F]BCPP-EF exhibited significant reductions ranging between 60 
and 70% of normal levels not only in the nigrostriatal pathway with abundant DA 
neurons but also in extra-striatal non-DA regions such as the cortex (H). No signifi-
cant decreases in the VT of [
18F]BCPP-EF were observed in the cerebellum.
Since the chronic treatment with MPTP, known as a DA specific toxin, unex-
pectedly induced decreases in MC-I activity in extra-striatal non-DA regions, 
another monoaminergic neuronal system of 5-HT was further evaluated. In the 
normal monkey brain, [11C]DASB binding to SERT was high in the striatal and mid-
brain regions (Figure 6A), while [18F]MPPF binding to 5-HT1AR was high in the 
cortical regions (B). The quantitative analysis of [11C]DASB revealed significantly 
lower SERT availability throughout the brain in MPTP-treated monkey, except the 
raphe nucleus (Figure 6C), than in normal monkeys (A). The reduction in [11C]
DASB availability to SERT was the greatest in the occipital cortex (19.7% of nor-
mal); intermediate in the frontal, parietal, and temporal cortices (50.0, 40.7, and 
51.6% of normal); smaller in the caudate (60.3% of normal); and the smallest in the 
putamen and SNc (66.0 and 67.7% of normal). In contrast, no significant changes 
were observed in [18F]MPPF binding to 5-HT1AR throughout the brain between 
normal (Figure 3B) and MPTP-treated monkeys (D).
In order to assess the relationship between MC-I and DA and 5-HT neuronal 
systems in MPTP-treated monkey brains, the degrees of reductions in DAT mea-
sured using [11C]PE2I, DAS measured using [11C]6MemTyr in the nigrostriatal 
pathway (caudate, putamen, and SNc), and SERT measured using [11C]DASB in 
Mitochondria and Brain Disorders
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Figure 5. 
Effects of the MPTP treatment on PET images of DA and MC-I in living brains of conscious monkeys. PET 
scans were conducted for 91 min using [11C]PE2I for DAT (A and E) and [18F]BCPP-EF for MC-I (D and H) 
and for 60 min using [11C]6MemTyr for DAS (B and F) and [11C]Raclopride for D2R (C and D). VT images 
of [18F]BCPP-EF (D and H) were created using a Logan graphical plot analysis with metabolite-corrected 
plasma input. BPND images of [
11C]PE2I (A and E) and 11C-Raclopride (C and G) and multiple-time 
graphical analysis Ki images of [11C]6MemTyr (B and F) were created using the corresponding TACs in the 
cerebellum as input functions.
Figure 6. 
Effects of the MPTP treatment on PET images of 5-HT in living brains of conscious monkeys. PET scans were 
conducted for 91 min with [11C]DASB for SERT (A and C) and [18FMPPF for 5-HT1AR (B and D). BPND 
images of [11C]DASB (A and C) and [18F]MPPF (B and D) were created using the corresponding TACs in the 
cerebellum as input functions.
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the nigrostriatal and cortical (frontal, occipital, temporal, and parietal cortices) 
regions were plotted against those in MC-I measured using [18F]BCPP-EF. Positive 
correlations were observed between the ΔBPND of [
11C]PE2I and ΔVT of [
18F]
BCPP-EF and between ΔKi of [11C]6MemTyr and ΔVT of [
18F]BCPP-EF in the 
nigrostriatal regions. In addition to the DA system, a positive correlation was noted 
between the ΔBPND of [
11C]DASB and ΔVT of [
18F]BCPP-EF in the cortical regions, 
while no correlation was found between ΔBPND of [
11C]DASB and ΔVT of [
18F]
BCPP-EF in the nigrostriatal regions.
4.3 Discussion
The administration of MPTP causes the slow progressive loss of DA neurons 
over a period of several months, and the decrease in nigrostriatal DA levels is 
responsible for the motor symptoms of MPTP-treated animals, resembling clinical 
symptoms in PD patient. Thus, impaired ETC for OXPHOS due to a MC-I defi-
ciency may account for neuronal cell death in PD. Alternatively, the MC-I defi-
ciency in nigrostriatal DA system of PD patients may be secondary to mitochondrial 
damage due to oxidative stress. MC-I is a site of ROS production and is particularly 
vulnerable to oxidative damage [57]. The results of the present study showing a 
deficiency in presynaptic DA activity in the nigrostriatal pathway were consistent 
with the conventional theory shown above.
In contrast, the present study applying [18F]BCPP-EF, a novel PET probe for 
MC-I, demonstrated that systemic and chronic MPTP treatments induced neuronal 
damage not only in the nigrostriatal DA pathway but also in the 5-HT neuronal 
system in the cortex of the monkey brain. Recent clinical studies suggested that 
in addition to motor symptoms, which are exclusively related to the nigrostriatal 
DA system, PD is a disease associated with non-motor symptoms, such as depres-
sion and cognitive deficits, which may be related to changes in other monoamines 
(noradrenaline and serotonin) in extra-striatal regions [58]. Lewy body and neurite 
deposition, a pathological hallmark of PD, occurs within the raphe nucleus contain-
ing 5-HT neurons of the caudal brainstem [59]. Decreases in 5-HT concentrations 
have been reported in the cortical regions of the postmortem brains of PD patients 
[60]. Furthermore, PET imaging on non-depressed PD patients revealed diffuse 
reductions in SERT availability throughout the brain [61] and decreased 5-HT1AR 
binding in the brains of non-depressed and depressed PD patients [62]. The present 
results obtained in MPTP-treated monkeys were consistent with the recent clinical 
observations on 5-HT abnormalities in PD patients, which cannot be diagnosed by 
PET measurements of dopaminergic parameters only.
5. Conclusion
This chapter introduced the potential of [18F]BCPP-EF as a PET probe for the 
noninvasive and quantitative imaging of MC-I activity in the living brain. The 
detectability of MC-I impairments using [18F]BCPP-EF for neuronal damage in AD 
appears to be superior to the assessment of glucose metabolism measured using 
conventional [18F]FDG. Furthermore, impaired serotonergic neuronal function in 
cortical regions suggests a relationship with depressive syndrome in PD patients. 
PET imaging of mitochondria function using [18F]BCPP-EF will provide novel 
insights into the pathology, diagnosis, and treatment efficacy assessments of a wide 
range of neurodegenerative diseases, including AD, PD, HD, ALS, and MS.
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